Search
for

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community is there any news about pp405 please

      in Update  11 upvotes 1 year ago
      There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

      community PP405 2a study was a safety study. Some rational explaining.

      in Research/Science  22 upvotes 6 months ago
      The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
      PP405 Identity Research

      community PP405 Identity Research

      in Research  292 upvotes 7 months ago
      PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

      community Don't use PP405 from everychem. it is likely fake.

      in Research/Science  65 upvotes 8 months ago
      PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

      community PP405 is nothing but a scam and Pelage know it.

      in Chat  78 upvotes 6 months ago
      PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.